RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant
Go back to RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.88 +0.02 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.86 | 52 Week High | $16.54 | |||
| Open | $0.86 | 52 Week Low | $8.10 | |||
| Day High | $0.94 | P/E | N/A | |||
| Day Low | $0.86 | EPS | $0.00 | |||
| Volume | 72,908 | |||||
